The lung exercise machine market size is projected to expand from USD 1.17 billion in 2025 and USD 1.22 billion in 2026 to USD 1.52 billion by 2031, registering a CAGR of 4.40% between 2026 to 2031. This report is Segmented by Device Type (Mechanical Resistance Trainers, Incentive Spirometers, and More), Application (COPD Rehabilitation, Post-Operative Pulmonary Therapy, and More), End User (Hospitals & Clinics, Home Care Settings, Rehabilitation Centers, Sports Institutions), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Multi-ball exercisers cater to pediatric and geriatric users with their engaging visual cues but lack the reimbursement support of higher-evidence categories, limiting their market share. Semiconductor shortages have extended lead times for electronic trainers, prompting some providers to maintain mechanical trainers as a risk mitigation strategy. However, as chip supplies stabilize between 2027 and 2028, the revenue mix is expected to shift further toward digitally enabled devices.
Europe's regulatory environment presents a mix of opportunities and challenges. Planned adjustments to MDR/IVDR in 2027 aim to expand pathways for breakthrough devices and regulatory sandboxes, while also imposing stricter post-market evidence requirements for software-as-a-medical-device, increasing cost pressures. Despite these challenges, strong public-health reimbursements, an aging population, and growing environmental health awareness ensure a stable baseline demand.
Asia-Pacific is projected to be the fastest-growing region, with a compound annual growth rate of 4.96%. China, with its 50.6 million COPD patients, represents a significant market opportunity. However, limited spirometry adoption delays diagnosis and subsequent device uptake. While urban hospitals in Beijing, Shanghai, and Guangzhou are piloting AI trainers, nationwide implementation depends on clearer reimbursement policies. In India, rising COPD cases due to particulate-matter exposure and biomass fuel usage contrast with the limited availability of structured pulmonary-rehabilitation units in tertiary hospitals.
Global Lung Exercise Machine Market Trends and Insights
Global COPD Cases Surge, Prompting Increased Demand for Post-COVID Pulmonary Rehabilitation
In 2024, global cases of COPD reached 213.4 million, resulting in 3.7 million deaths. Ambient particulate matter has emerged as the leading risk factor, surpassing smoking. India faces a growing burden due to deteriorating urban air quality. Randomized trials conducted in 2024 demonstrated that two-week respiratory muscle programs effectively restored forced vital capacity and reduced systemic inflammation in long-COVID patients. In response, CMS expanded pulmonary rehabilitation coverage in 2026 to include post-COVID patients and established virtual supervision guidelines. These policy changes have reduced cost barriers and integrated devices into chronic care pathways, driving growth in the lung exercise machine market.Home-Based Respiratory Therapy Gains Traction
In June 2025, CMS approved reimbursements for at-home non-invasive ventilation, removing the requirement for facility supervision and legitimizing remote pulmonary rehabilitation sessions. A 2024 study revealed that internet-of-things respiratory programs significantly improved the six-minute walk distance by 63.74 meters and reduced 90-day rehospitalizations compared to center-based care. Data from the United Kingdom indicate that home-based therapy users are younger and more socioeconomically disadvantaged, highlighting the role of tele-pulmonary rehabilitation in expanding access for underserved populations. CMS has extended telehealth flexibilities through 2027, allowing hospitals to bill for remote therapy sessions conducted at patients' homes. Device manufacturers have responded by acquiring digital diagnostics firms to integrate hardware, data, and services into seamless home-care ecosystems.Stringent Certification And Reimbursement Hurdles
In December 2025, the European Commission proposed revisions to the Medical Device Regulation, extending certificate validity while increasing post-market-surveillance requirements for software-driven trainers. These changes are expected to raise both the documentation workload and associated costs. In November 2024, Becton Dickinson received an FDA warning for quality-system deficiencies, resulting in a significant USD 83 million remediation accrual, which underscores the financial impact of non-compliance. The 2026 Physician Fee Schedule introduced a -2.5% efficiency adjustment, reducing reimbursements for pulmonary rehabilitation and prompting providers to consider lower-cost devices or fewer supervised sessions. Coverage under CPT codes 94625 and 94626 remains restricted to GOLD Stage II-plus COPD patients or those with post-COVID indications, excluding asthma-only users, which limits potential growth for certain device categories.Other drivers and restraints analyzed in the detailed report include:
- Connected and AI-Driven Trainers on the Rise
- Gamified Biofeedback Boosts Patient Adherence
- Low Awareness In Emerging Markets
Segment Analysis
In 2025, incentive spirometers accounted for 36.3% of revenue, reflecting their established role in surgical pathways. However, mechanical resistance trainers are projected to grow at a 4.67% CAGR, surpassing the overall lung exercise machine market growth rate by a quarter-point. This trend is supported by data showing that preoperative inspiratory-muscle conditioning significantly reduces pulmonary complications. Electronic smart trainers, featuring Bluetooth chips, pressure sensors, and coaching algorithms, are driving market growth through premium pricing and recurring software subscriptions.Multi-ball exercisers cater to pediatric and geriatric users with their engaging visual cues but lack the reimbursement support of higher-evidence categories, limiting their market share. Semiconductor shortages have extended lead times for electronic trainers, prompting some providers to maintain mechanical trainers as a risk mitigation strategy. However, as chip supplies stabilize between 2027 and 2028, the revenue mix is expected to shift further toward digitally enabled devices.
Complete Report Scope:
- By Device Type
- Mechanical Resistance Trainers
- Electronic / Smart Trainers
- Incentive Spirometers
- Positive Expiratory Pressure (PEP) Devices
- Multi-Ball Respiratory Exercisers
- By Application
- COPD Rehabilitation
- Post-operative Pulmonary Therapy
- Asthma Management
- Sports & Fitness Performance
- Geriatric Lung Health
- By End User
- Hospitals & Clinics
- Home Care Settings
- Rehabilitation Centers
- Sports Institutions
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
In 2025, North America accounted for 39.61% of the revenue, driven by favorable coverage decisions and strong telehealth penetration. The Centers for Medicare & Medicaid Services extended virtual supervision through 2027, ensuring reimbursement for connected trainers used in patient homes. Although a -2.5% efficiency cut has reduced session margins, providers have mitigated the impact by shifting to lower-overhead home programs and selecting devices that digitally document outcomes. ResMed, headquartered in San Diego, has leveraged its expertise in hardware and diagnostics integration, supported by its acquisition of VirtuOx, which combines sleep-testing and pulmonary-rehabilitation data into a unified cloud platform.Europe's regulatory environment presents a mix of opportunities and challenges. Planned adjustments to MDR/IVDR in 2027 aim to expand pathways for breakthrough devices and regulatory sandboxes, while also imposing stricter post-market evidence requirements for software-as-a-medical-device, increasing cost pressures. Despite these challenges, strong public-health reimbursements, an aging population, and growing environmental health awareness ensure a stable baseline demand.
Asia-Pacific is projected to be the fastest-growing region, with a compound annual growth rate of 4.96%. China, with its 50.6 million COPD patients, represents a significant market opportunity. However, limited spirometry adoption delays diagnosis and subsequent device uptake. While urban hospitals in Beijing, Shanghai, and Guangzhou are piloting AI trainers, nationwide implementation depends on clearer reimbursement policies. In India, rising COPD cases due to particulate-matter exposure and biomass fuel usage contrast with the limited availability of structured pulmonary-rehabilitation units in tertiary hospitals.
List of Companies Covered in this Report:
- AirPhysio
- AirPhysio Pty Ltd
- Beckton Dickinson
- Beijing Konted Medical Technology
- Besmed Health Business
- Boen Healthcare
- Breathslim
- Cardinal Health
- Kompaniya Dinamika
- Koninklijke Philips
- Leventon, S.A.U.
- Medtronic
- Nidek Medical India Private Limited
- PN Medical Inc.
- POWERbreathe International Ltd.
- Resmed
- Smiths Group
- Medtronic
- Trudelmed
- Vyaire Medical
- Wintersweet Medical
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AirPhysio
- AirPhysio Pty Ltd
- Becton, Dickinson and Company
- Beijing Konted Medical Technology
- Besmed Health Business
- Boen Healthcare
- Breathslim
- Cardinal Health Inc.
- Kompaniya Dinamika
- Koninklijke Philips N.V.
- Leventon, S.A.U.
- Medtronic plc
- Nidek Medical India Private Limited
- PN Medical Inc.
- POWERbreathe International Ltd.
- ResMed Inc.
- Smiths Medical
- Medtronic plc
- Trudelmed
- Vyaire Medical Inc.
- Wintersweet Medical
